The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline ...

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

Looking into the current session, Sanofi Inc. SNY shares are trading at $49.35, after a 0.24% increase. Moreover, over the ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the China-bas ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...